1. A DV ER T I SEMENT FEAT URE
Shanghai BIOON Group
Information Technology Co., Ltd
w w w.bioon.com Bioon.com
Bio-industrial parks in China:
Striking a Balance
The rapid growth of China’s economy is reflected in the Furthermore, I believe the small and medium-sized
dramatic rate of development observed in the nation’s enterprises engaged in short term development, for
biotech and pharmaceutical industry. Currently, there example, production of diagnostic reagents, may be bet-
are more than 300 contract research organizations ter suited to second-tier bio-industrial parks. In contrast,
(CROs) and 5,000 pharmaceutical companies in China. companies based on proprietary technology require a
The gross domestic product of China’s medical and long-term strategy and market orientation. As such, the
pharmaceutical industry exceeded US$140 billion in government plans a park’s development strategy based
2008, compared to only $1.2 billion in 1979. Growth on the local development situation and future goals in
of the Chinese market is providing a number of great order to strike a reasonable balance between me-too
opportunities for both domestic and foreign investors. companies and innovative ones.
The world’s top ten pharmaceutical companies have
About Dr. Fa-Bao Zhang: The founder of already invested in China-based production. Opportunities and challenges
BioonGroup and CEO of Shanghai BIOON
China has the world’s largest population, and the
Information Technology Co., Ltd.; Also
serves as the co-founder and secretary-
The difference between hotspot and country has undertaken sweeping reforms designed to
general of Life Science Awards (LSAC), a differentiation improve healthcare access in the country. At present,
member of the expert committee of China In China, local and national governments have integrat- China is actively promoting a rural health policy to acti-
Pharmaceutical Technology Transfer ed various resources into the building of bio-industrial vate and improve the health insurance for 800 million
Organization (CPTO), consultant of parks adopting the business model that first proved suc- rural farmers. This initiative undoubtedly represents a
national bioindustry parks. cessful in the US. Creation of bio-industrial parks is a huge number of opportunities for domestic and inter-
complex undertaking that presents challenges at every national pharmaceutical businesses. We believe that
BioonGroup, established since 2001 in step from idea to application. Following the success of an annual 25% growth rate of China’s pharmaceutical
China, as the leading service organization,
Wuxi AppTec Co. Ltd (Shanghai, China), a leading CRO industry will remain consistent for the next five years
provide latest news, instruments and
reagents information, professional
company; many bio-industrial parks began to seek out (the end of China’s twelfth Five-year Plan for Economic
consulting and marketing survey and and groom similar world class companies such as those Development).
analysis based on life sciences and providing outsourcing services or conducting research Harnessing these growth opportunities is a new
medicine. The divisions of BioonGroup and development (R&D). challenge. Each of the top ten pharmaceutical compa-
include six websites and three subbrands, Although the Chinese pharmaceutical outsourcing nies has entered China and is either building an R&D
e.g. BIOON, MedSci and BioInsight. Our market is growing rapidly, this does not mean that all center or renting space for R&D operations. However,
mission is that building a rapid and bio-industrial parks should focus on CROs. In my view, some companies are still hesitating, wondering about the
convenient platform to link supplies to
these bio-industrial parks should pay more attention to uncertainty of Chinese policy and marketing. Certainly,
pharmaceutical, biotech, and research
customers. Meanwhile, over 1.5 million the following three factors: local investment environ- adapting to a rapidly changing market is a difficult chal-
registered and permission users’ database ment, geographical location and high-tech talent. Based lenge for small and medium-size enterprises.
could help to delivery enterprises news and on the differentiation of these factors, and a need for
products information to them via Electronic specialty and high-quality science parks, a national strat- Balance soft environment and hard
Direct Mail (EDM) or Direct Mail (DM). All egy was devised and executed for the whole of China. infrastructure
BIOTECH IN CHINA
these work aim to accelerate China biotech The challenge for the strategy is matching the needs Most of the bio-industrial parks have made large
industry development.
of companies to local resources. R&D companies need investments in construction infrastructure, includ-
Currently, the page views of our websites
a technology pool (such as academic institutions) and ing first-rate buildings and advanced equipment and
are more than 2 million each day. Most of investigative talent; clinical trial companies focus on instruments. The true accelerators of enterprise devel-
who possess Master or Doctoral degrees patient populations and better hospitals; manufactur- opment, however, are more important than these solid
and over 70% of the registered members ing enterprises are concerned with cost reduction. Bio- structures. These catalyst include optimised training
come from the top 50 Chinese universities industrial parks should, therefore, introduce targeted systems, efficient talent recruitment services, frequent
and institutes. companies and develop their specialty according to the academic communication, professional law services
appropriate differentiation within the biotech industry. and intellectual property rights consulting. As a lead-
CONTACT DETAILS: ing and professional consulting company, we provide
Balancing me-too and innovation these services to developing enterprises. From talent
BioonGroup
It is necessary for the government to encourage Chinese recruitment, market expansion to finance channels,
Rm 302, Bulg 2, 51 Longwu Rd, Shanghai
companies to be innovative. While innovation is very we provide a one-stop service.
200232,China
important but relatively weak as a basis for China’s phar- Dr. Fabao Zhang
Tel: +86-21-54485309 maceutical industry, me-too, outsourcing, in-licensing fbzhang@bioon.com
Fax: +86-21-54485087 and out-licensing are other essentials for the growth of
www.bioon.com the industry. In most of China’s second-tier cities, me- www.bioon.com www.bioon.com.cn
Email: marketing@bioon.com; too and outsourcing would be the better option as a job.bioon.com www.bbs.bioon.com
editor@bioon.com focal point for development activities. www.bioevent.cn www.medsci.cn
S14
ADVERTISER RETAINS SOLE RESPONSIBILITY FOR CONTENT